Tecentriq 1,200 MG/20 ML vial 20ML
Ended Awarded Last action
- Contract number
- SPE2DR26FMEA8
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $33,184
Award facts
- Contract value 100% obligated
- $33,183.65 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $33,183.65 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Tecentriq (atezolizumab) 1,200 mg/20 ml vials. The delivery order, issued on December 8, 2025, with an ultimate completion date of December 30, 2025, was awarded without a set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. No subcontractors were identified in the award documentation.
This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion government-wide acquisition strategy designed to supply Department of Defense healthcare facilities worldwide. The underlying IDC, designated SPE2DR and valued at $499,999,999, was awarded on November 13, 2025, and establishes DMS Pharmaceutical Group as a regional prime vendor contractor authorized to provide a comprehensive range of pharmaceutical products including branded and generic medications, biologics, and medical consumables. The firm fixed-price structure and DLA's Medical Supply Chain division oversight position this contractor as a critical supplier supporting recurring pharmaceutical needs across the global military medical system.
Quick answers
Who was awarded contract SPE2DR26FMEA8?
SPE2DR26FMEA8 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 8, 2025.
How much is contract SPE2DR26FMEA8 worth?
The government has obligated $33,184 on SPE2DR26FMEA8.
Is contract SPE2DR26FMEA8 an order under another contract?
Yes. SPE2DR26FMEA8 is a delivery order under SPE2DR25D9114, an indefinite delivery contract.
Was contract SPE2DR26FMEA8 competed?
The extent of competition for SPE2DR26FMEA8 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award